Last reviewed · How we verify
NCT02837419
Cost-effectiveness of Extracorporeal Life Support Treatment
trial testing Health related Quality of life EQ-5D in Critically Ill in 200 participants. Status unknown.
1 January 2020
Quick facts
| Lead sponsor | University Medical Center Groningen |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 1 December 2017 |
| Primary completion | 1 January 2020 |
| Estimated completion | 1 January 2020 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- Health related Quality of life EQ-5D
Conditions studied
- Critically Ill — all drugs for Critically Ill →
Sponsor
University Medical Center Groningen
Who can join
18 and older, any sex, with Critically Ill. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates patients on ECLS treatment as considered appropriate with mortality and health related Quality of life and costs.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Cost-effectiveness in extracorporeal life support in critically ill adults in the Netherlands.
Oude Lansink-Hartgring A, Dos Reis Miranda D, Donker DW, Maas JJ, et al · · 2018 · cited 4× · PMID 29523153 · DOI 10.1186/s12913-018-2964-6 -
Five Years After Extracorporeal Membrane Oxygenation: A Prospective Cohort Study of Health-Related Quality of Life and Patient Outcomes.
Jolink FEJ, Onrust M, Dos Reis Miranda D, Mandigers L, et al · · 2025 · cited 2× · PMID 41091003 · DOI 10.1097/ccm.0000000000006900
Verify or expand the search:
- PubMed search for NCT02837419
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Critically Ill
Currently open trials in the same condition.
- NCT07222007 — Induction Agent Choice With Early Mortality and Prognostic Outcomes in Critically Ill Patients · recruiting
- NCT07143695 — Parasternal Intercostal Muscle Thickening as an Additive Weaning Criterion · NA · recruiting
- NCT06473844 — Efficacy of SGLT2 Inhibitors in Adults With Sepsis · NA · recruiting
- NCT05055830 — Opportunistic PK/PD Trial in Critically Ill Children (OPTIC) · recruiting
- NCT05112328 — The Effects of Pancreatic Enzyme Supplementation in Critically Ill Patients on Enteral Feeding · NA · recruiting
Other University Medical Center Groningen trials
Trials by the same sponsor.
- NCT06647602 — Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy · not yet recruiting
- NCT06809946 — Feasibility of Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy · Phase 2 · not yet recruiting
- NCT07527390 — CANagliflozin In DIALysis Patients · Phase 4 · not yet recruiting
- NCT07439237 — Implant-supported Maxillary Overdentures; a 15-years Evaluation · not yet recruiting
- NCT07275437 — Effectiveness and Safety of Uptitration of Guideline Directed MEdical Therapy in Heart Failure With Reduced Ejection Fra · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02837419 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Medical Center Groningen
- Last refreshed: 25 September 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02837419.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing